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Krabbe disease is a lysosomal storage disorder that affects several species including humans, 
mice and dogs. It is caused by mutations in the GALC gene that encodes galactosylceramidase. 
These mutations result in lowered activity of this lysosomal enzyme which has an important 
role in myelin turnover. As a consequence, individuals with Krabbe disease show signs of 
neurological disease and pathological features occur in the central and peripheral nervous 
systems. These pathological features are globoid cells, demyelination and inflammation. 
Mechanisms behind the development of these features remain unclear despite genetic, 
biochemical, cellular and clinical studies. Genetic studies in Krabbe disease have allowed the 
development of PCR-based tests which have been proven to be a useful tool in identifying 
carriers of the disease. The recent diagnosis of Krabbe disease in the Australian Working 
Kelpie provides a new opportunity for genetic and pathological studies to further characterise 
Krabbe disease.  
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Introduction 
 
Lysosomal Storage Disorders (LSDs) are a group of severe and rapidly progressive inherited disorders 
that affect humans and animals (Platt and Walkley, 2004). Krabbe disease is a LSD in which the 
pathology and molecular basis has been investigated in humans, mice and dogs. Despite these 
investigations gaps in knowledge still remain, particularly in our understanding of Krabbe disease 
mechanisms (Suzuki, 2003; Wenger et al., 2001). The recent diagnosis of Krabbe disease in the 
Australian Working Kelpie provides a new opportunity to further characterise the disease (Taylor, 
unpublished data). 
 
The following paper will review current knowledge of the pathology and molecular basis of Krabbe 
disease in humans, mice and dogs. It will also discuss investigations of the pathophysiology of Krabbe 
disease and the benefits of PCR-based tests for identification of carriers in both humans and animals. 
 
1. Lysosomal storage disorders 
 
Lysosomes are organelles that contain hydrolytic enzymes. These enzymes catabolise both endogenous 
and cell ingested material (Frandson et al., 2003). As such, lysosomes have an important role in cell 
metabolism and consequently cell function. LSDs are a group of inherited diseases occurring in humans 
and animals when there is lowered activity of a lysosomal enzyme (Platt and Walkley, 2004). The result 
of this enzyme deficiency is the accumulation or storage of non-catabolised substrates. This storage 
initiates a cascade of pathological dysfunction typically observed in the nervous system (Platt and 
Walkley, 2004).  
 
The majority of LSDs are of autosomal recessive inheritance and are rare in occurrence. The incidence of 
LSDs as a group in humans is 1 in 8000 live births (Meikle et al., 1999; Platt and Walkley, 2004). 
Despite the rarity of these diseases, they have devastating effects, and impose a significant burden on 
families and the community. Due to their involvement in the nervous system many LSDs result in 
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neurological dysfunction and mental retardation (Platt and Walkley, 2004). The treatment options for 
LSDs remain limited despite ongoing research (Kolter and Sandhoff, 2006; Platt and Walkley, 2004; 
Wenger et al., 2001). 
 
LSDs may be classified on the basis of the substrate being accumulated or the molecular defect which 
causes the disease (Platt and Walkley, 2004). Table 1 summarises classification based on the 
accumulated substrate.  
 
Table 1: Categories of LSDs based on accumulated substrate  
(Modified from Hopwood et al., 2004) 
Classification Accumulated Substrate Disease Examples Species 
Lipidoses Lipids. Includes 
sphingolipids, cholesterol 
esters and triglycerides 
Krabbe disease 
Gaucher disease 
Wolman disease 
Humans, mice, dogs, sheep, monkey 
Humans, mice, dogs, sheep 
Humans, mice 
Mucopolysaccharidoses 
(MPS) 
Mucopolysaccharides 
(glycoaminoglycans) 
MPS I 
MPS II 
MPS III 
Humans, mice, cats, dogs 
Humans, mice, dogs, 
Humans, dogs, cattle 
Glycogenosis Glycogen Pompe disease Humans, mice, cattle, dogs, cats 
Glycoproteinoses Glycoproteins and/or 
oligosaccharides 
Fucosidosis 
α- mannosidoses 
Sialidosis 
Humans, dogs 
Humans, cattle, mice, guinea pig, cats 
Humans, mice 
 
 
2. Krabbe disease 
 
Krabbe disease (OMIM #245200, OMIA #1140/000578), also known as globoid cell leukodystrophy, is a 
LSD with autosomal recessive inheritance that affects several species including humans, rhesus 
macaques, dogs, mice (Suzuki and Suzuki, 1985; Suzuki, 2003) and sheep (Pritchard et al., 1980). It is 
caused by mutations in the GALC gene that encodes the lysosomal enzyme galactosylceramidsase 
(galactocerebroside β-galactosidase) (Luzi et al., 1997; Rafi et al., 1995; Sakai et al., 1996; Victoria et 
al., 1996). As a result of these mutations the activity of galactosylceramidase is lowered (Wenger et al., 
2001) and the degradation of galactosylceramide during myelin turnover is impaired (Suzuki, 2003; 
Wenger et al., 2001). 
 
Galactosylceramidase activity plays a crucial role in the catabolism of the myelin sheath of axons during 
myelin turnover (Wenger et al., 2001). The myelin sheath acts as an electrical insulator that increases the 
ability of responses to be transmitted through the nervous system (Behan, 2004). It is composed of 30% 
protein and 70% lipid. Of this lipid component, 29% is galactolipid, and the majority of this is 
galactosylceramide (galactocerebroside) (Lefebvre and Vartanian, 2002). Myelin turnover is the process 
by which these myelin components are broken down and replaced (Lefebvre and Vartanian, 2002). In 
humans this process is initiated within eighteen months of birth (Wenger et al., 2001). Myelination and 
myelin turnover is also initiated early in canine development occurring within two to three months of 
birth in domestic dogs (Lord and Duncan, 1987). The role of galactosylceramidase in myelin turnover is 
to catabolise the myelin lipid, galactosylceramide into galactose and ceramide (Lefebvre and Vartanian, 
2002; Wenger et al., 2001). In the normal nervous system these substances are processed by the lysosome 
(Kolter and Sandhoff, 2006) and recycled components are able to enter the remyelination pathway 
(Lefebvre and Vartnanian, 2002; Suzuki, 2003). Remyelination does not occur effectively in Krabbe 
disease (Suzuki, 2003; Wenger et al., 2001), but myelin turnover continues (Suzuki, 2003). 
Galactosylceramidase also has a role in the catabolism of psychosine which is produced during myelin 
turnover (Suzuki, 2003). Psychosine is a cytotoxic intermediate in the biosynthesis of ceramide (Suzuki, 
2003).  The role of galactosylceramidase in myelin turnover means that its deficiency results in 
demyelination which alters neuronal conduction and so produces signs of neurological dysfunction. The 
course of this neurological dysfunction is rapidly progressive and fatal (Suzuki, 2003; Wenger et al., 
2001).  Bone marrow transplantation is one of the few treatments available to manage Krabbe disease 
(Suzuki, 2003; Wenger et al., 2001). However, the success of this treatment option is dependent on rapid 
diagnosis, it entails substantial risks and it does not cure the disease. Bone marrow transplantation only 
succeeds in slowing the progression of Krabbe disease and improving clinical signs (Suzuki, 2003). 
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2.1 Krabbe disease in humans 
 
Krabbe disease in humans is typically a neurodegenerative disease of infancy, but there have been rare 
instances where Krabbe disease has been diagnosed in older children and even adults (Wenger et al., 
2001). Symptoms of Krabbe disease usually indicate involvement of the central nervous system (CNS), 
particularly the cerebellum (Jacob et al., 1973; Suzuki, 2003) which controls the refinement and 
execution of movement and the co-ordination of muscle activity (Starr and Taggart, 2001). The disease 
affects all white matter tracts in the CNS and the Schwann cells of the peripheral nerves. As the disease 
progresses clinical signs of loss of higher cerebral functions develop (Suzuki, 2003; Wenger et al., 2001). 
The cerebrum is the region of the brain responsible for the initiation of movement and conscious 
sensation (Starr and Taggart, 2001). The usual age of onset for infantile Krabbe disease is 3-6 months 
and initially children show signs of hyperirritability, are hypersensitive to the external environment, and 
show stiffness of the limbs (Suzuki and Suzuki, 1985; Suzuki, 2003; Wenger et al., 2001). The symptoms 
of Krabbe disease progress rapidly as psychomotor functions deteriorate until the children become 
unresponsive and unaware of their surroundings. Children affected with Krabbe disease rarely survive 
beyond two years of age (Suzuki, 2003; Wenger et al., 2001).  
 
Histopathological examination of the CNS in individuals affected with Krabbe disease reveals myelin 
degeneration, oligodendrocyte death, astrocytosis, and globoid cell formation. All pathological features 
are observed in the white matter of the brain, spinal cord and Schwann cells of peripheral nerves (Jacob 
et al., 1973; Krabbe, 1916; Schochet et al., 1976). Globoid cell formation is a particular characteristic of 
the disease, and when this is observed diagnosis is rarely in doubt (Yunis and Lee, 1976).   
 
The diagnosis of Krabbe disease is currently made by a combination of methods including 
histopathologic examination, enzymic assay and genetic testing (Suzuki, 2003; Wenger et al., 2001). 
Historically the disease was diagnosed post mortem by histopathologic observations of central nervous 
tissue (Jacob et al., 1973; Krabbe, 1916; Schochet et al., 1976). This method continues to be used in 
conjunction with an enzyme assay to confirm diagnosis (Suzuki, 2003; Wenger et al., 2001). This 
enzyme assay was developed in the 1970s (Miyatake and Suzuki, 1972a; Suzuki and Suzuki, 1970) and 
measures the activity level of galactosylceramidase (Miyatake and Suzuki, 1972a). The activity of 
galactosylceramidase is used to determine the phenotype of an individual as affected or normal. While 
the enzyme assay is effective in diagnosing Krabbe disease, it cannot be used to conclusively identify 
carriers (Wenger et al., 2001). Recently, the advent of molecular technology has allowed for mutations 
causing the deficiency of galactoslyceramidase to be identified (Fu et al., 1999; Rafi et al., 1995). The 
identification of these mutations has also facilitated the confirmation of Krabbe disease diagnosis through 
the development of PCR-based tests designed to check for the presence these mutations (Fu et al., 1999; 
Rafi et al., 1995; Wenger et al., 2001). Genetic testing is a particularly useful diagnostic tool in families 
where parents are known carriers. In this situation PCR-based tests are employed in prenatal diagnosis 
using a sample of amniotic or chorionic villus cells (Wenger et al., 1997). 
 
2.2 Animal models 
 
Animal models are valuable resources where investigation in human subjects may be limited by ethical 
concerns or limited availability. Since Krabbe disease primarily affects children ethical concerns of 
disease investigation in humans can be manifold (Platt and Walkley, 2004; Suzuki and Suzuki, 1985). 
There is also the rarity and variability of the disease which challenges experimental design and analysis 
(Wenger, 2000). Animal models can overcome both these difficulties, providing test subjects which can 
be used in studies to increase understanding and knowledge of the disease, as well as in treatment trials to 
improve the quality of life for affected individuals (Wenger, 2000). 
 
Krabbe disease research has several different animal models available for investigation. These animal 
models include the rhesus monkey (Baskin et al., 1998; Borda et al., 2008), the sheep (Pritchard et al., 
1980), the mouse (Duchen et al., 1980) and the dog (McGraw and Carmichael, 2006; Wenger et al., 
1999). Of these models, the mouse model, known as the twitcher mouse has been studied in greatest 
depth (Duchen et al., 1980; Kobayashi et al., 1980; Kobayashi et al., 1982; LeVine et al., 1994; Nagara et 
al., 1982; Sakai et al., 1996). Despite this, it is important to consider that each animal model has their 
own strengths and weaknesses (Wenger, 2000), and information drawn from experiments using a single 
animal model can be used in conjunction with information from experiments in a different model to 
further the understanding of Krabbe disease. 
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2.3 The twitcher mouse 
 
The spontaneous murine model of Krabbe disease, the twitcher mouse, was reported in 1980 by Duchen 
and others. The original investigation into the twitcher mouse confirmed that the disorder was transmitted 
in an autosomal recessive manner and that it was caused by a deficiency of galactosylceramidase 
(Duchen et al., 1980). This study also recognised the similarities between Krabbe disease in the twitcher 
mouse and humans. As a consequence, it established the twitcher mouse as an important animal model 
for Krabbe disease. 
 
In the mouse, clinical signs of Krabbe disease begin at approximately 20 days and include weight loss, 
head tremors and weakness in the hind limbs (Duchen et al., 1980). These signs, particularly limb 
weakness, are indicative of peripheral nervous system (PNS) and spinal cord involvement. The tremors 
and poor coordination are common indicators of cerebellar disease that are present in all the animal 
models, including canine, human and murine forms of Krabbe disease.  There is limited knowledge on 
the involvement of the PNS in human Krabbe disease, although it is a well established feature of murine 
and canine forms of the disease. Death in twitcher mice usually occurs by day 40 (Nagara et al., 1982) 
and no twitcher mouse has lived beyond three months without treatment (Duchen et al., 1980). 
 
The histopathological features observed in the CNS of the twitcher mouse closely resemble those 
occurring in the human disease (Duchen et al., 1980; Kobayashi et al., 1980; Suzuki and Taniike, 1995). 
The white matter of the CNS shows demyelination, oligodendrocyte death, astrocytosis, microgliosis and 
globoid cell formation (Duchen et al., 1980).  
 
The twitcher mouse makes a good animal model for the study of Krabbe disease since it is a naturally 
occurring enzymatically authentic model of the disease (Duchen et al., 1980). The small generation 
interval of mice makes them particularly suitable for experiments that require large numbers of affected 
or carrier animals (Kobayashi et al., 1980; Suzuki and Suzuki, 1985). The identification of the mutation 
causing Krabbe disease in the twitcher mouse by Sakai and others (1996) has led to the development of a 
PCR-based test. The test involves extracting a sample of DNA from the mice and using specific 
oligonucleotide primers in a PCR to amplify a region of DNA sequence that includes the disease 
mutation site (Sakai et al., 1996). The resultant fragment is then digested with a restriction enzyme which 
cleaves the DNA at the site of the mutation, before undergoing gel electrophoresis to determine the size 
and pattern of the resultant DNA bands. This process allows the individual mouse from which the DNA 
was sampled to be genotyped as a homozygous affected, heterozygous carrier or homozygous normal 
based on the pattern of the enzyme digestion (Sakai et al., 1996). The genotyping of mice using this test 
facilitates the diagnosis of Krabbe individuals prior to the onset of clinical signs and performance of 
experimental procedures (Biswas et al., 2002; Giri et al., 2006). The use and development of this PCR-
based test is also an advantage for management of the twitcher model. 
 
3. Krabbe disease in canines 
 
Canine Krabbe disease was first diagnosed in West Highland White (WHW) and Cairn Terriers 
(Fankhauser et al., 1963; Wenger et al., 1999). It has since been reported in other dog breeds including 
the Irish Setter (McGraw and Carmichael, 2006), and the Bluetick Hound (Boysen et al., 1974). The 
reporting of Krabbe disease in these breeds has led to positive outcomes which are described in Table 2. 
In particular the development of a PCR-based test in the WHW and Cairn Terriers has led to the 
establishment of a research colony and widespread testing for carriers of Krabbe disease in this breed 
(Wenger et al., 1999). 
 
The clinical signs of Krabbe disease in canines appear at approximately three months of age (Jortner and 
Jonas, 1968) and are similar to those of the twitcher mouse. Signs include muscle weakness, ataxia and 
paraplegia of the hind limbs (Boysen et al., 1974; Jortner and Jonas, 1968). As in the human and murine 
forms of Krabbe disease, the canine disease shows signs typical of a multi-focal neurological disease 
affecting the CNS and PNS, particularly spinal cord and cerebellum. Euthanasia is usually requested by 
the owners before the disease can progress to the final stages due to the severity of the disease (Jortner 
and Jonas, 1968; Wenger et al., 1999). In the clinical investigation on the Bluetick Hound conducted by 
Boysen and others (1974), the disease was allowed to progress for two months until one animal could no 
longer walk, being paralysed in both the hind and fore limbs. Soon after reaching this stage the animal 
died.  
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Table 2: Benefits of Reporting Krabbe Disease in Dog Breeds 
Breeds Benefits Outcomes 
West Highland 
White Terriers* 
 
Veterinarian and breed society 
awareness  
(McGraw and Carmichael, 
2006; Wenger et al., 1999; 
Boysen et al., 1974) 
Krabbe disease does not remain 
undiagnosed 
(Jortner and Jonas, 1968; McGraw and 
Carmichael, 2006) 
Cairn Terriers* 
 
Identification of mutation 
causing Krabbe disease in the 
GALC gene  
(McGraw and Carmichael et al., 
2006; Victoria et al., 1996; 
Wenger et al., 1999) 
Development of PCR-based tests 
(McGraw and Carmichael, 2006; 
Victoria et al., 1996) 
Irish Setter
+ 
 
 
Development of PCR-based 
tests  
(McGraw and Carmichael 
2006) 
Carriers are identified and removed 
from breeding stock (McGraw and 
Carmichael, 2006; Wenger et al,. 
1999) 
 
Research colonies are established 
(Wenger et al., 1999) 
Bluetick
#
 Hound 
*Research colonies established and breed screening program in place (Wenger et al., 1999). 
+
PCR-based 
test available and a breed screening program for Krabbe disease is being developed (McGraw and 
Carmichael, 2006). 
#
 No further studies of Krabbe disease beyond the neuropathological investigation 
conducted by Boysen and others (1974). 
 
The histopathological features of the canine disease are similar to those in humans, with extensive 
demyelination and oligodendrocyte and Schwann cell death, reactive astrocytosis and globoid cell 
formation (Jortner and Jonas, 1968). It has been noted in the dog that globoid cells are more prevalent in 
areas of severe myelin degeneration (Jortner and Jonas, 1968; Yunis and Lee, 1976).  The appearance of 
axonal spheroids has also been noted in the histopathology of the canine disease, but not in the human 
disease. In the neuropathological study conducted by Jortner and Jonas (1968) they reported the irregular 
appearance of axons which were swollen and pale. This description matches that of axonal spheroids 
which have been noted in other LSDs (Crawley and Walkley, 2007; Platt and Walkley, 2004) but not in 
human Krabbe disease (Jacob et al., 1973; Schochet et al., 1976; Wenger et al., 2001; Suzuki, 2003).  
 
Canine Krabbe disease may be diagnosed based on the result of the galactosylceramidase assay (Suzuki 
et al., 1974) or a PCR-based test where one is available for the known mutation in a breed (Wenger et al., 
1999). When diagnosis is based on the enzyme assay, affected individuals have a lower 
galactosylceramidase activity than normal and heterozygotes (Suzuki et al., 1974). The 
galactosylceramidase assay is the same method used to diagnose Krabbe disease in humans (Wenger et 
al., 2001), and is a reliable and effective technique of identifying diseased but not carrier individuals. 
This technique was used by Suzuki and others (1974) to confirm that canine Krabbe disease is an 
enzymatically authentic model of the disease. In breeds such as the WHW Terrier, Cairn Terrier and Irish 
Setter where a PCR-based test is available, diagnosis may be based on this (McGraw and Carmichael, 
2006; Wenger et al., 1999). 
 
3.1 The canine model 
 
The occurrence of Krabbe disease in dogs has led to their use as an animal model (Wenger et al., 1999). 
The canine model of Krabbe disease is more appropriate for studies involving the clinical and 
pathophysiological aspects of the disease (Wenger et al., 1999; Wenger, 2000). It is more suitable for 
these types of studies than the twitcher mouse because the greater size and complexity of the canine brain 
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allows clearer dissection of the different regions of the nervous system (Suzuki and Suzuki, 1985), 
correlation with clinical signs of dysfunction and more reliable comparison to the human brain (Yunis 
and Lee, 1976). The canine model is also useful since the behavioural changes that occur in larger 
animals affected with LSDs are more similar to the psychomotor changes that occur in humans (Platt and 
Walkley, 2004) and can be more easily monitored in an animal such as the dog which has complex social 
interactions with people and its environment. 
 
4. Krabbe disease in the Australian Working Kelpie 
 
In 1998-1999, three related Australian Working Kelpie pups from the same property in Tamworth, NSW 
were presented to a veterinarian with signs of neurological disease and clinical investigations were 
performed. In these clinical examinations, each of the pups showed signs of disease similar to the clinical 
signs of Krabbe disease described in WHW and Cairn Terriers by Jortner and Jonas (1968). However, 
since Krabbe disease had not been previously reported in the Australian Working Kelpie, the first animal 
presented was treated for suspected toxoplasmosis until test results were returned negative. Following the 
negative toxoplasmosis results the first two pups were surrendered to Elizabeth Macarthur Agricultural 
Institute (EMAI) for investigation of neurological disease. 
 
At EMAI, preliminary histopathology was performed and it was found the brain tissue displayed the 
globoid cell lesions characteristic of Krabbe disease (Taylor, unpublished data). This prompted 
investigators at EMAI and the University of Sydney to conduct a galactosylceramidase assay in the third 
pup. It was found that the third Australian Working Kelpie pup had low galactosylceramidase activity 
indicative of Krabbe disease (Taylor, unpublished data).  
 
To date, there has been no published data characterising Krabbe disease in Australian Working Kelpies. 
This is a concern as it means veterinarians are not aware that Krabbe disease can occur in this breed and 
it may go undiagnosed. This is undesirable as Krabbe disease is an inherited disorder and widespread use 
of a phenotypically normal heterozygote carrier over the breed could lead to increased incidences of 
Krabbe disease in the Australian Working Kelpie. Further, there is another inherited neurological 
disorder called hereditary cerebellar abiotrophy (CA) which affects the Australian Working Kelpie breed 
(Thomas and Robertson, 1989). The clinical signs of this disorder are similar to the signs seen in Krabbe 
disease affected Kelpies and include ataxia, hypermetria and dysmetria of the hind limbs (Thomas and 
Robertson, 1989). The similarity in clinical signs of CA and Krabbe disease may mean that cases of 
Krabbe disease are being misdiagnosed, especially since CA is known in the veterinary community and 
by the breed society to be a genetic disorder which affects the Australian Working Kelpie breed.  
 
5. Pathogenesis 
 
In LSDs it is important to understand how the genetic deficiency in lysosomal enzyme activity and the 
storage of the non-catabolised substrate are responsible for pathology (Platt and Walkley, 2004). 
Recently, the focus of pathological studies on LSDs has been in finding the link between the observed 
clinical signs of the disease and the histopathological and biochemical features (Borda et al., 2008; 
LeVine et al., 1994; Platt and Walkley, 2004). 
 
The pathogenesis of Krabbe disease is caused by an underlying genetic malfunction in the production of 
galactosylceramidase. This leads to a deficiency of this enzyme which results in the impaired degradation 
of galactosylceramide, the primary substrate of galactosylceramidase, and psychosine, its secondary 
substrate (Suzuki, 2003). Unlike most other LSDs the primary substrate is not found at elevated levels in 
the nervous tissue of Krabbe affected individuals (Suzuki, 2003). This suggests that galactosylceramide 
is not stored and that Krabbe disease is not a typical example of a LSD. Instead, the secondary substrate 
has been found at high concentrations (Igisu and Suzuki, 1984; Kobayashi et al., 1980; Svennerholm et 
al., 1980) and is believed to cause the pathological features of the disease in what is known as the 
'psychosine hypothesis' (Miyatake and Suzuki, 1972b). 
 
5.1 The pathogenic cascade 
 
The pathogenic cascade of Krabbe disease is outlined in Figure 1. The deficiency of 
galactosylceramidase results in the insufficient catabolism of both galactosylceramide and psychosine 
during myelin turnover (Suzuki, 2003). Galactosylceramide is a main component of myelin, which is 
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produced by the oligodendrocytes of the CNS and the Schwann cells of the PNS (Lefebvre and 
Vartnanian, 2002). During myelin turnover galactosylceramide is broken down into galactose and 
ceramide by galactosylceramidase (Platt and Walkley, 2004) and these products are then used in a 
separate remyelination pathway (Suzuki, 2003). In Krabbe disease the breakdown of galactosylceramide 
does not occur. Instead, galactosylceramide along with other myelin debris triggers a microglial response 
that results in the formation of globoid cells, a characteristic histopathological feature of Krabbe disease 
(Borda et al., 2008; Suzuki, 2003). 
 
 
 
Figure 1: Pathogenic cascade of Krabbe disease. Adapted from Suzuki (2003). NOTE: 
Appearance of axonal spheroids has only been described in canine Krabbe disease.   
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Psychosine is also produced in the oligodendrocytes during normal myelin turnover, but is normally 
broken down immediately by galactosylceramidase so its cytotoxic effects are not demonstrated (Suzuki, 
2003). In the Krabbe affected brain, psychosine is allowed to accumulate within the oligodendrocytes 
(Borda et al. 2008; LeVine, 1994; Suzuki, 2003). According to the 'psychosine hypothesis' this results in 
oligodendrocyte apoptosis causing demyelination, and the resulting myelin debris triggers an 
inflammatory response of astrocytosis and microgliosis (Suzuki, 2003). 
 
5.2 Oligodendrocytes and demyelination 
 
Oligodendrocytes are the glial cells in the CNS that produce myelin (Beham, 2004). One oligodendrocyte 
may have many processes that extend and wrap around a number of axons, myelinating them (Behan, 
2004; Lefebvre and Vartnanian, 2002). In Krabbe disease, swelling of the oligodendrocytes has been 
observed (Taniike et al., 1999). This swelling results in oligodendrocyte dysfunction and occurs before 
myelin turnover and the consequential demyelination begins (LeVine et al., 1994; Taniike et al., 1999). 
Dysfunctional oligodendrocytes then undergo programmed cell death known as apoptosis (Taniike et al., 
1999) resulting in the reduced oligodendrocyte numbers seen in lat stage disease (Duchen et al., 1980; 
Jortner and Jonas, 1968). 
 
The timing of oligodendrocyte death and demyelination during brain development has been investigated 
in the twitcher mouse (LeVine et al., 1994; Taniike et al., 1999). These investigations are based on the 
regional difference in brain myelination rates during postnatal brain development (LeVine et al., 1994). 
In the study conducted by Taniike and others (1999) it was observed that oligodendrocytes that initiate 
myelination early in brain development were the first to undergo apoptosis. This study supports the 
findings of LeVine and others (1994) who reported severe oligodendrocyte death and demyelination in 
the brainstem and cerebellum, which are myelinated early in development, and limited evidence of 
oligodendrocyte death in the cerebrum until very late stage disease. The findings of LeVine and others 
(1994) can also be related to the clinical course of the disease in humans, mice and canines which begins 
with signs of PNS, spinal cord and cerebellar dysfunction (Duchen et al., 1980; Jortner and Jonas et al., 
1968; Wenger et al., 2001) and progresses to show cerebral indications of disease, particularly in human 
Krabbe disease (Suzuki et al., 2003; Wenger et al., 2001). 
 
It is also speculated that demyelination of axons caused by the oligodendrocyte death may result in 
axonal and eventual neuronal loss similar to that in longstanding lesions of multiple sclerosis (MS), a 
demyelinating disease of humans (Adams, 1989; Gonzalez-Scarano and Baltuch, 1999). In MS, axons 
that remain demyelinated eventually die back to the neuron body resulting in further neurological 
dysfunction. Axonal loss has not been reported in Krabbe disease (Jacob et al., 1973; Jortner and Jonas et 
al., 1968; Suzuki, 2003), but this is possibly due to rapid progression of the disease (Suzuki, 2003; 
Wenger et al., 2001) which means individuals die before axonal loss secondary to demyelination can 
begin. 
 
The mechanism causing programmed cell death in the oligodendrocytes of the Krabbe affected brain is 
not known. It has been speculated that tumour necrosis factor alpha (TNF-α), a cytokine produced by 
microglia may have a role in the inflammatory and immune funtcions(Taniike et al., 1999). However, the 
'psychosine hypothesis' is widely accepted and it is thought that the accumulation of psychosine results in 
oligodendrocyte death, and consequential demyelination (Formichi et al., 2007; Giri et al., 2006; Igisu 
and Suzuki, 1984; LeVine et al., 1994; Suzuki, 2003; Taniike et al., 1999). Both may contribute to the 
rapid myelin loss which occurs. 
 
5.3 The psychosine hypothesis 
 
The 'psychosine hypothesis' was first put forward by Miyatake and Suzuki (1972b) who found that 
Krabbe disease patients were unable to hydrolyse psychosine. The 'psychosine hypothesis' is supported 
by a large number of studies and has yet to be conclusively disproved. Igisu and Suzuki (1984), 
Kobayashi and others (1987) and Svennerholm (1980) have all identified increased levels of psychosine 
in the white matter of the Krabbe affected brain. The cytotoxic effects of psychosine have also been 
demonstrated in both animal models (Miyatake and Suzuki, 1972b) and in vitro (Giri et al., 2006). 
 
The 'psychosine hypothesis' is also supported by a study conducted into the pattern of psychosine 
accumulation using Fourier-transform infrared microcspectroscopy (FT-IR). FT-IR allows the 
accumulation of psychosine to be measured in situ (LeVine et al., 1994). It was found that psychosine 
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accumulated most in the hindbrain, a site where myelination occurs early in development (LeVine et al., 
1994). The next area which had a high concentration of psychosine was the cerebellum. The cerebrum 
had the lowest concentration of psychosine. This pattern of psychosine accumulation matched the pattern 
of oligodendrocyte apoptosis also found in this study. The pattern of psychosine accumulation found in 
this study correlates with both the myelination and myelin turnover pattern of the developing brain and 
the clinical course of Krabbe disease.  Myelination and myelin turnover begins in the cervical spinal cord 
and proceeds rostrally through the brainstem to the cerebrum (LeVine et al., 1994; Lord and Duncan, 
1987). The clinical course of Krabbe disease shows motor dysfunction due to spinal cord and PNS 
involvement, and ataxia and weakness indicative of cerebellar disease. In human Krabbe disease these 
symptoms progress to cerebral signs of disease as psychomotor development and learned behaviours 
regress in the terminal stages (Suzuki, 2003). 
 
Recent research into the mechanism behind apoptosis of oligodendrocytes also supports the basic 
premise of the 'psychosine hypothesis.' In a recent study it was proposed that the increased levels of 
psychosine in Krabbe disease results in the activation of pro-inflammatory cytokines, such as TNF-α  and 
interleukin-6 (IL-6) and it is in this way that psychosine induces oligodendrocyte apoptosis (Formichi et 
al., 2007). This proposal was based on the level of cytokines observed in psychosine treated peripheral 
blood leukocytes and peripheral blood monocytes (Formichi et al., 2007). Similarly, in a separate study, 
psychosine was also found to be an apoptosis activator (Giri et al., 2006). However, in this investigation 
it was found that psychosine activates the phospholipidase A2 system (PLA2) and this mediates 
apoptotic oligodendrocyte death (Giri et al., 2006). This finding was based on the accumulation of 
lysophosphatidylcholine (LPC), a product of PLA2, in the brains of Krabbe affected mice and humans, 
and the dose-dependant increase of LPC in cultured cells treated with psychosine (Giri et al., 2006). It is 
possible that there is a link between the two studies and the activation of the PLA2 system may be due to 
the cytokines activated by psychosine. However, further research is required before a solid conclusion 
can be drawn on this hypothesised pathogenic mechanism. 
 
5.4 Microglial activation 
 
Microglia are the resident macrophages of the CNS (Behan, 2004). The multinucleate globoid cells of 
Krabbe disease are believed to be activated microglia that phagocytose free galactosylceramide and other 
myelin degradation products. However, there has been some debate about the origin of globoid cells due 
to their perivascular location (Alroy et al., 1986a; Alroy et al., 1986b; Yunis and Lee, 1976). Some 
investigators believe that globoid cell formation could be due to the invasion and fusion of blood-derived 
macrophages which cross the blood-brain barrier (Alroy et al., 1986a; Borda et al., 2008). It is thought 
that by understanding the origin of globoid cells their role in the inflammatory response of Krabbe 
disease will become clear, along with potential avenues for ameliorating the severity of the disease 
(Borda et al., 2008).  
 
In a recent study by Borda and others (2008) biochemical markers were used in order to determine the 
origin of globoid cells. This study found that globoid cells contained markers specific to both resident 
microglia and blood-derived macrophages. This suggests that globoid cells consist of both types of 
macrophages. The possibility that both types of macrophages are involved in globoid cell formation 
means that cytokines released from microglia could have a role in the inflammatory response observed in 
Krabbe disease.  
 
The release of cytokines such as TNF-α and IL-6 by microglia has been well documented in several other 
demyelinating diseases such as MS, experimental autoimmune encephalomyelitis and canine distemper 
virus (CDV) (Gonzalez-Scarano and Baltuch, 1999; Grone et al., 2000; Markus et al., 2002). Cytokines 
released by microglia may be pro- or anti-inflammatory, amplifying the effects of inflammation as well 
as protecting the CNS (Gonzales-Scarano and Baltuch, 1999; Grone et al., 2000). It has also been 
speculated that microglia have a role in the normal clearance of myelin break down products and may 
release TNF-α and IL-6 in this process (Borda et al., 2008). In Krabbe disease the release of these 
cytokines may result in the formation of globoid cells as well as other pathological features of the disease 
(Borda et al., 2008). 
 
5.5 Astrocytosis 
 
Normal astrocytes in the brain contribute to the formation of the blood brain barrier, and maintain 
nutrition and ion concentrations essential to neuronal function (Behan, 2004). Reactive astrocytosis 
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occurs when astrocytes proliferate in response to brain injury (Behan, 2004; Little and O'Callaghan, 
2001). This reactive astrocytosis is what has been observed in histopathological examinations of brain 
tissue from individuals affected with Krabbe disease (Jacob et al., 1973; Jortner and Jonas, 1968; Itoh et 
al., 2002; Yunis and Lee 1976). It is thought that reactive astrocytosis occurs in an effort to 'seal off' 
damaged tissues and prevent spread of the injury (Buffo et al., 2008). This may be effective and useful in 
an infectious disease such as CDV (Markus et al., 2002). However investigators remain unsure of the 
function of reactive astrocytosis in a genetic disorder like Krabbe disease, where neuropathology is 
global throughout the nervous system. 
 
The mechanisms behind the initiation of reactive astrocytosis in Krabbe disease are also unclear, 
although this is a common finding in most lysosomal storage disorders. It is thought that astrocytosis is 
triggered by the release of cytokines (Itoh et al., 2002; Little and O'Callaghan, 2001). However, it is not 
known if these cytokines are released by the microglia (Itoh et al., 2002) or normal astrocytes which are 
reacting to the presence of apoptotic oligodendrocytes (Little and O'Callaghan, 2001). 
 
5.6 Axonal spheroids 
 
Axonal spheroids are swellings of axons. They occur in both the white and grey matter of the CNS and 
PNS (Platt and Walkley, 2004). They have been noted in many neuropathies including several LSDs 
(Platt and Walkley, 2004) but have only been observed in the canine form of Krabbe disease (Jortner and 
Jonas, 1968). As a consequence of this restricted occurrence there is limited knowledge on the formation 
of axonal spheroids in Krabbe disease. In the majority of neuropathies featuring spheroidosis including 
other lysosomal disorders, the axonal spheroids are believed to be an indicator of axonal transport 
dysfunction (Crawley and Walkley, 2007; Itoh et al., 2006). 
 
6. Investigation of pathophysiology 
 
To have a full understanding of a genetic disorder, the pathophysiology of the disease must be 
investigated at several different levels. These levels include investigation of the underlying genetic 
defect, biochemical studies of the proteins and enzymes involved in disease pathogenesis, cellular studies 
of the structures involved in the pathology and clinical examinations of the individuals. 
  
6.1 Genetic studies 
 
Genetic investigations into inherited disorders like LSDs are able to increase understanding by 
ascertaining what causes the underlying enzyme or protein deficiency involved. Methods which have 
been used in genetic studies of Krabbe disease include gene mapping (Zlotogora et al., 1990), protein 
purification (Chen and Wenger, 1993; Sakai et al., 1994), mutation analysis (Rafi et al., 1995; Victoria et 
al., 1996) and in vitro expression studies (Victoria et al., 1996). 
 
Protein purification and sequencing has allowed the cDNA of the GALC gene to be cloned and 
sequenced facilitating mutation analysis (Chen et al., 1993; Sakai et al., 1994; Sakai et al., 1996; Victoria 
et al., 1996). Protein sequence was back translated into mRNA to obtain the cDNA nucleotide sequence 
(Sakai et al. 1994). The purification of galactosylceramidase was difficult and the first studies attempting 
to do this reported very low yields (Chen et al., 1993; Chen and Wenger, 1993; Sakai et al., 1996). This 
was the main difficulty in attempts to sequence the GALC gene which was one of the last lysosomal 
enzyme genes to be sequenced.  
 
Once the GALC cDNA was cloned and sequenced, mutation analysis was conducted. The aim of 
mutation analysis is to identify what changes in the gene cause the enzyme deficiency. In Krabbe disease 
over forty human mutations have been identified (Fu et al., 1999; Wenger et al., 1997) and two canine 
mutations have been identified (McGraw and Carmichael, 2006; Victoria et al. 1996). Mutation analysis 
can be linked to biochemical and expression studies and can be used to design PCR-based tests such as 
those available for human mutations, the twitcher mouse and the WHW and Cairn terrier. 
 
Expression studies are generally conducted in vitro to confirm that mutations identified do lead to 
enzyme deficiency and are not simply polymorphisms. An expression study confirmed that one of the 
transversions identified in the GALC gene of the WHW and Cairn Terriers was a disease causing 
mutation, while the other transversion was a polymorphism that did not affect galactosylceramidase 
expression (Victoria et al., 1996).   
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PCR-based tests are used to genotype individuals and are most useful in identifying phenotypically 
normal carriers of a genetic disorder such as Krabbe disease. PCR-based tests involve taking a DNA 
sample from a suspected carrier. The DNA sample may be derived from blood (Victoria et al., 1996), 
tissue (Sakai et al., 1994), saliva or aminotic cells in the case of pre-natal detection of a disorder (Wenger 
et al., 2001). The sample forms the basis for a PCR along with specific oligonucleotide primers which 
incorporate a restriction site, to amplify the region of DNA sequence that includes the disease mutation 
site identified by the mutation analysis (Victoria et al., 1996; Sakai et al., 1994). This produces a 
fragment of DNA which may then be digested with a restriction enzyme as in the PCR-based tests for the 
twitcher and WHW and Cairn terrier mutations (Victoria et al., 1996; Sakai et al., 1994). In the twitcher 
and WHW and Cairn terrier DNA tests, the restriction enzyme cuts a fragment with an affected allele, 
while the fragment containing the normal allele remains whole (Victoria et al., 1996; Sakai et al., 1994). 
These digested fragments then undergo gel electrophoresis to determine the genotypes. 
 
6.2 Biochemical studies 
 
Biochemical studies are useful in pathophysiological investigations because they can identify the 
enzymes, substrates and mediators involved in the disease. They can also be used to confirm the enzyme 
deficiency, relating back to genetic studies and can contribute to understanding in cellular investigations. 
Methods of biochemical investigation include enzyme assays and expression studies.  
 
Enzyme assays such as the galactosylceramidase assay which is used to confirm Krabbe disease 
diagnosis can be used in biochemical studies to establish enzyme activity levels in a variety of different 
tissues (Miyatake and Suzuki, 1972a).  This establishes where the deficiency is located and if it affects 
the whole body or just one area or organ system. Assays can also be used to isolate biochemicals 
involved in the disorder. In Krabbe disease the isolation of psychosine in the brain of Krabbe affected 
patients but not in controls established that psychosine was involved in the disorder (Igisu and Suzuki, 
1984; Svennerholm et al., 1980).  
 
Expression studies into the role of psychosine have established the role of substrates and the pathways 
they trigger (Giri et al., 2006). This increases understanding of the effects biochemical pathways have on 
cellular metabolic pathways. 
 
6.3 Cellular investigation 
 
Investigation into the pathophysiology of a disease using cellular investigation techniques can assist in 
establishing the location of biochemical lesions in LSDs. Cellular investigations can also be used to study 
the structure and function of normal cells (Platt and Walkley, 2004) since most cellular studies report the 
changes in cells due to disease (Jacob et al., 1973; Jortner and Jonas, 1968).  Cellular investigations can 
also be used to investigate the timing of pathological changes in tissues (LeVine et al., 1994) and these 
might be correlated to changes observed in clinical examinations. In Krabbe disease cellular structure has 
been investigated using a variety of histological techniques including light microscopy, electron 
microscopy, and immunohistochemistry. The histological and immunohistochemical techniques which 
have been successfully used in the cellular investigation into the pathophysiologic features of Krabbe 
disease are outlined in Table 3. 
 
6.4 Clinical examination 
 
Clinical examination contributes to the pathophysiological investigation and allows repeated assessment 
of the impact of disease on neural control of sensation and movement. Clinical examinations are most 
useful when used in context with the other methods of investigation. 
 
To gain a full understanding of Krabbe disease pathophysiology investigations need to examine several 
different aspects of the disease. The nature and difficulties of Krabbe disease research means that a full 
study linking each of these methods of investigation has not been attempted. This can make it difficult to 
integrate studies which only focus on one of these areas.  
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Table 3: Histological Techniques Commonly Used in the Investigation of Krabbe Disease 
Stain 
Histological/ 
Histochemical/ 
Immunohistochemical and 
Technique 
Use 
Hematoxylin and 
Eosin 
 (H+E) 
Histological stain, used in 
conjunction with light 
microscopy 
Identifies general tissue structure (Jortner and Jonas, 
1968; Wenger et al., 1999) and can be used to highlight 
the appearance of globoid cells (Wenger et al., 1999; 
Yunis and Lee, 1976) 
Periodic Acid-
Schiff (PAS) 
Histological stain, used in 
conjunction with light 
microscopy 
Binds to glycogen stores (Yunis and Lee, 1976) Globoid 
cells are PAS positive (Jortner and Jonas 1968; LeVine et 
a., 1994; Yunis and Lee, 1976) 
Luxol Fast Blue  
(LFB) 
Histological stain, used in 
conjunction with light 
microscopy 
Identifies myelin and indicates areas of demyelination 
(Borda et al., 2008; Yunis and Lee, 1976) 
Myelin Basic 
Protein Antibody 
 (MBP) 
Immunohistochemical/antib
ody stain, used in 
conjunction with light 
microscopy 
Identifies myelin (Itoh et al., 2002) 
Glial Fibrillary 
Acidic Protein 
Antibody (GFAP) 
Immunohistochemical/antib
ody stain, used in 
conjunction with light 
microscopy 
Identifies astrocyte hypertrophy (LeVine et al., 1994) 
Lectin Stains 
Histochemical, used in 
conjunction with light and 
electron microscopy 
Binds to specific carbohydrates on cellular structures and 
has been used to identify carbohydrates within storage 
bodies (Alroy et al., 1986a, 1986b) 
In Krabbe disease lectin staining was used in an attempt 
to identify the nature of globoid cell inclusions 
Ubiquitin 
Antibody 
Immunohistochemical/antib
ody stain used in 
conjunction with light 
microscopy 
Identifies axonal spheroids in which ubiquitin is 
accumulated (Crawley and Walkley, 2006; Platt and 
Walkley, 2004) 
 
7. Molecular basis of Krabbe disease 
 
Galactosylceramidase is encoded by the GALC gene in both humans and animals (Wenger et al., 1997). 
It was mapped to human chromosome 14, mouse chromosome 12 (Zlotogora et al., 1990) and dog 
chromosome 8 (NCBI, 2008). There is significant homology in the gene sequence between the three 
species and there are close structural similarities between the human, mouse and dog GALC genes (Sakai 
et al., 1996; Victoria et al., 1996; Wenger et al., 2000).  
 
7.1 Human GALC mutations  
 
Mutation analysis of the human GALC gene was facilitated by the cloning and sequencing of GALC 
cDNA (Chen et al., 1993; Rafi et al., 1995; Sakai et al., 1994). This allowed DNA obtained from Krabbe 
affected individuals to be sequenced and analysed against the normal GALC gene. To date there have 
been over forty mutations identified that cause the galactosylceramidase deficiency of Krabbe disease 
(Fu et al., 1999; Wenger et al., 1997).  The most common mutation in the European population is a 30kb 
deletion which is associated with a C to T transversion at cDNA position 502 (Rafi et al., 1995; Wenger 
et al., 1997). The C to T transversion was a polymorphism which does not affect galactosylceramidase 
activity. The large 30kb deletion affects the production of galactosylceramidase since it removes a 
significant portion of the enzyme coding region (Rafi et al., 1995).  In the Japanese population, the most 
common mutation is a 12bp deletion with a 3bp insertion. This results in the deletion of 5 amino acids 
and the insertion of 2 amino acids which impacts on the quaternary structure of galactosylceramidase 
(Tatsumi et al., 1995; Wenger et al., 1997).  
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The large number of mutations means that there are also a large number of possible genotypes. This 
means that compound heterozygotes may occur (Wenger et al., 1997). Compound heterozygotes are 
individuals which have two different mutated alleles at the same locus. In many cases where compound 
heterozygotes are identified they have low to intermediate galactoslyceramidase activities and may not 
present with clinical signs of Krabbe disease or they may present with clinical signs which are atypical 
(Wenger et al., 1997).  This has made it difficult to correlate phenotype with genotype in human Krabbe 
disease (Fu et al., 1999; Wenger et al., 1997; Wenger et al., 2000). 
 
This difficulty in correlating phenotype with genotype may also limit the efficacy of PCR-based tests as a 
definitive diagnostic tool where human Krabbe disease may be suspected in an individual with no family 
history of the disease (Wenger et al., 2000). Despite this, PCR-based tests remain a helpful tool in 
confirming diagnosis and in research situations (Wenger et al., 2000). These tests are especially useful in 
families that are known to carry a mutation for Krabbe disease. In this situation PCR-bases tests have 
been used to identify the genetic status in utero from a sample of DNA collected from amniotic fluid 
(Wenger et al., 1997). 
 
7.2 Canine GALC mutations 
 
Two different mutations in the canine GALC gene have been identified in three breeds (McGraw and 
Carmichael, 2006; Victoria et al., 1996). It is likely, considering the genetic diversity of dog breeds and 
the number of mutations in the genetically diverse human population, that further mutations identified in 
other dog breeds will be unique.  
 
The first canine mutation was identified in the WHW and Cairn Terriers when the canine GALC cDNA 
was cloned (Victoria et al., 1996). The canine GALC cDNA is similar to the human GALC cDNA with 
88-90% identity (Victoria et al., 1996). The mutation causing Krabbe disease in the WHW and Cairn 
Terriers was an A to C transversion which resulted in hydrophobic tyrosine being substituted with 
hydrophilic serine (Victoria et al., 1996). This amino acid substitution caused a structural change to 
galactosylceramidase that resulted in the enzyme having no biological activity (Victoria et al., 1996).  
 
The second canine mutation was identified in an Irish Setter family by cDNA mutation analysis 
(McGraw and Carmichael, 2006). It is different from the ‘terrier’ mutation since it is a 78 nucleotide 
insertion that results in the absence of a stop codon in the open reading frame (McGraw and Carmichael, 
2006). Given the mutation, the mRNA is unlikely to be translated into functional protein, but it could 
result in the altered mRNA being translated into a larger than normal enzyme. Enzyme expression studies 
have shown that if galactosylceramidase is translated it does not have any biological activity (McGraw 
and Carmichael, 2006). 
 
7.3 Availability and use of PCR-based tests 
 
The identification of mutations in the GALC gene has allowed PCR-based tests to be developed (Fu et 
al., 1999; McGraw and Carmichael et al., 2006; Sakai et al., 1996; Victoria et al., 1996; Wenger et al., 
1997). These PCR-based tests are used to confirm the genetic status of an individual using a small 
sample of DNA (Wenger et al., 1997). 
 
In research situations PCR-based tests are used to ascertain the genetic status of animals before the onset 
of clinical signs (Biswas et al., 2002; Giri et al., 2006; Wenger et al., 2001), allowing experimental 
procedures to be performed in the early stages of disease progression. This is particularly important when 
conducting treatment trials (Suzuki, 2003; Wenger et al., 2001) since it has been found in humans that for 
treatments such as bone marrow transplant and enzyme replacement therapy to have some effect they 
must be commenced as early as possible, preferably before the onset of clinical signs (Wenger et al., 
1999).  
 
The identification of carriers using PCR-based tests is particularly useful in both human and animal 
situations since carriers cannot be identified reliably using the enzyme assay (Wenger et al., 1997; Suzuki 
et al., 1972). In humans, the identification of carriers is used in genetic counselling (Wenger et al., 2001) 
since the birth of a child with Krabbe disease can be a devastating and heart-wrenching event for families 
(Jacob et al., 1973).  The identification of carriers in animals by PCR-based tests has led to an 
implementation of a breeding program in the WHW and Cairn Terriers (Wenger et al., 1999). In this 
breeding program identified carriers are removed from the companion animal breeding stock and may be 
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referred to researchers for the ongoing establishment of a research colony (Wenger et al., 1999). A 
similar process occurred in the Irish Setter breed, but no research colony has been established (McGraw 
and Carmichael, 2006). The removal of carrier animals from breeding stock is done with the aim of 
eradicating Krabbe disease from these breeds (Wenger et al., 1999). 
 
Conclusion 
 
PCR-based tests are important tools in managing Krabbe disease in human and animal situations. They 
have been developed through the identification of mutations causing Krabbe disease in the GALC gene 
which encodes galactosylceramidase, the lysosomal enzyme which is deficient in this disease. These 
genetic studies along with biochemical and cellular investigations have led to increased understanding of 
the pathogenesis of Krabbe disease. However, despite this increased understanding there still remain gaps 
in the knowledge and many mechanisms behind events in the pathogenic cascade of Krabbe disease have 
not been elucidated. The occurrence of Krabbe disease in another dog breed provides an opportunity to 
further increase the understanding of Krabbe disease pathology. It is possible that the mutation 
underlying Krabbe disease in the Kelpie may be identified in the future by sequencing the GALC gene in 
the affected dogs. Mutation analysis and development of a PCR-based test may then lead to the 
implementation of a heterozygote carrier screening program similar to that in WHW and Cairn terriers 
enabling the control and eradication of Krabbe disease from Australian Working Kelpies. 
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